Extended Data Fig. 3: Study design. | Nature Medicine

Extended Data Fig. 3: Study design.

From: Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial

Extended Data Fig. 3

*Represents danuglipron (PF-06882961) dose or matching placebo. 12 planned participants per cohort: 9 active and 3 placebo. 28 days of inpatient dosing for all cohorts. Titration occurred over the duration of the 28 days in the 120 mg BID ST, 200 mg QD CR, and 120 mg QD cohorts. BID, twice daily; CR, controlled-release; QD, once daily; ST, slow titration.

Back to article page